ulcerative colitis
Gastroenterology · 2013–2025
47decisions
13medicines
33carried consumer input
291individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Treatment of immune-mediated inflammatory diseases (IMIDs) in paediatric patients under 18 years of age, with disease severity considered sufficient to cause… | Jul 2025 | Recommended with restriction | 6 individuals |
| infliximab Multiple indications including rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults and children (6 to 17 years), refractory Crohn's disease,… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing… | Mar 2025 | Recommended with restriction | input received |
| infliximab Amendment to restriction level for continuing treatment of severe active rheumatoid arthritis, severe Crohn disease, severe chronic plaque psoriasis, severe… | Mar 2025 | Recommended with restriction | input received |
| ustekinumab Severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and moderate to severe… | Mar 2025 | Recommended with restriction | input received |
| vedolizumab Dose escalation from 8-weekly to 4-weekly intravenous maintenance treatment in adults with moderate to severe ulcerative colitis or severe Crohn disease who… | Nov 2025 | Not recommended | input received Colitis Australia |
| etrasimod Treatment of patients 16 years and older with moderate to severe ulcerative colitis (MSUC). | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Treatment of paediatric severe chronic plaque psoriasis, severe Crohn disease, moderate to severe ulcerative colitis, and complex refractory fistulising Crohn… | Mar 2024 | Recommended | input received Colitis Australia |
| ustekinumab Severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, and complex refractory fistulising Crohn disease. | Nov 2024 | Recommended | input received Colitis Australia |
| mirikizumab Treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response with, lost response to, or were intolerant to… | Jul 2023 | Recommended with restriction | input received Colitis Organisation |
| upadacitinib Moderate to severe ulcerative colitis in adult patients who have failed to achieve an adequate response, or are contraindicated, to conventional therapies. | Jul 2022 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Moderate to severe ulcerative colitis in adult patients who have had an inadequate response or intolerance to conventional therapy. | Jul 2022 | Recommended with restriction | 2 individuals Colitis Australia |
| ozanimod Treatment of moderate to severe ulcerative colitis in adults who have had inadequate response, lost response, or intolerance to prior therapies… | Mar 2022 | Recommended with restriction | 1 individuals Colitis Australia · Gastroenterological Society |
| adalimumab Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa, chronic plaque psoriasis, ulcerative colitis, Crohn's disease, and… | Nov 2022 | Not recommended | 1 individuals |
| ozanimod Treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response, lost response, or were intolerant to standard… | Nov 2022 | Recommended with restriction | none received |
| mesalazine Management of an acute episode of mild to moderate ulcerative proctitis (suppository); ulcerative colitis and Crohn disease (modified release granules). | Mar 2020 | Recommended | 1 individuals |
| infliximab Treatment of adults with severe active rheumatoid arthritis, ankylosing spondylitis, severe refractory Crohn's disease, complex refractory fistulising Crohn's… | Nov 2020 | Recommended with restriction | input received Colitis Australia · Parallel- Group |
| mesalazine Treatment of mild to moderate ulcerative colitis and maintenance of remission in adults. | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| tofacitinib Treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response, lost response, or were intolerant to standard… | Nov 2020 | Recommended with restriction | 50 individuals Colitis Australia |
| vedolizumab Maintenance treatment for patients with moderate to severe ulcerative colitis (MSUC) and severe Crohn's disease (CD) who have responded to intravenous… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| infliximab Subsequent continuing treatment for severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe Crohn disease, moderate to severe… | Mar 2019 | Recommended with restriction | 3 individuals |
| tofacitinib Moderate to severe ulcerative colitis in adult patients who have had an inadequate response, lost response, or were intolerant to standard treatment. | Mar 2019 | Recommended with restriction | 7 individuals |
| adalimumab Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile idiopathic arthritis, severe… | Jul 2018 | Recommended | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| mesalazine Treatment of ulcerative colitis and Crohn disease in patients with documented hypersensitivity reaction to sulphonamides or intolerance to sulfasalazine. | Jul 2018 | Recommended with restriction | none received |
| budesonide Induction of remission in adult patients with mild to moderate active ulcerative colitis where 5-aminosalicylic acid (5-ASA) treatment is not sufficient or not… | Jul 2017 | Not recommended | input received Colitis Australia · Gastroenterological Society · Australian Inflammatory Bowel Disease Association |
| mesalazine Treatment of ulcerative colitis, including induction of remission and maintenance therapy in patients with documented hypersensitivity to sulphonamides or… | Mar 2017 | Recommended with restriction | none received |
| balsalazide Treatment of mild-to-moderate active ulcerative colitis, and maintenance of remission, in patients who are intolerant to sulfasalazine. | Nov 2017 | Deferred | none received |
| golimumab Treatment of moderate to severe ulcerative colitis in adult patients with inadequate response to conventional therapy. | Nov 2017 | Recommended with restriction | 21 individuals |
| infliximab Change to initial and continuing treatment restrictions for the biosimilar brand of infliximab (Renflexis) for severe active rheumatoid arthritis, ankylosing… | Nov 2017 | Recommended with restriction | none received |
| adalimumab Treatment of patients with moderate to severe ulcerative colitis (UC). | Mar 2016 | Recommended | 3 individuals |
| infliximab Biosimilar to Remicade for multiple indications including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and… | Nov 2016 | Recommended | none received |
| adalimumab Treatment of moderate to severe ulcerative colitis (UC) after failure of conventional agents (5-aminosalicylic acid compounds, corticosteroids, and… | Jul 2015 | Not recommended | 74 individuals |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| vedolizumab Treatment of moderate to severe ulcerative colitis in patients who have failed conventional therapy (5-aminosalicylates, corticosteroids, and immunomodulators)… | Mar 2015 | Recommended with restriction | 98 individuals |
| adalimumab Treatment of patients with moderate to severe ulcerative colitis (UC) after failure of conventional agents. | Nov 2015 | Not recommended | 3 individuals |
| mesalazine Treatment of ulcerative colitis in patients with hypersensitivity to sulfonamides or intolerance to sulfasalazine. | Nov 2015 | Recommended | none received |
| adalimumab Treatment of chronic refractory moderately to severely active ulcerative colitis in adult patients who have failed, are intolerant, or are contraindicated to… | Jul 2014 | Not recommended | 12 individuals |
| infliximab Treatment of moderate to severe ulcerative colitis in patients who have had an inadequate response to conventional therapy (5-aminosalicylates, azathioprine,… | Jul 2014 | Recommended with restriction | 4 individuals |
| vedolizumab Initial treatment of moderate to severe ulcerative colitis in patients who have failed to achieve adequate response to prior systemic therapy (corticosteroids… | Jul 2014 | Not recommended | 2 individuals |
| infliximab Initial treatment of moderate to severe ulcerative colitis in patients aged 6 and above who have had an inadequate response or intolerance to conventional… | Mar 2014 | Recommended with restriction | unclear |
| mesalazine Treatment of active mild to moderate ulcerative colitis and for the maintenance of remission. | Nov 2014 | Recommended with restriction | no section in document |
| mesalazine Treatment of acute ulcerative colitis of mild to moderate severity, and for maintenance of remission and/or long-term treatment of ulcerative colitis in… | Nov 2014 | Recommended with restriction | no section in document |
| budesonide Treatment of active rectal and rectosigmoid disease in ulcerative colitis. | Jul 2013 | Recommended | no section in document |
| infliximab Treatment of acute severe ulcerative colitis not responding to intravenous corticosteroids in patients aged 6 years or greater. | Mar 2013 | Not recommended | unclear |
| infliximab Treatment of acute severe ulcerative colitis not responding to intravenous corticosteroids in patients aged 6 years or older. | Nov 2013 | Recommended with restriction | input received |
| adalimumab Treatment of moderate to severe active ulcerative colitis in adult patients who have had inadequate response to conventional therapy or who are intolerant to… | Nov 2013 | Not recommended | no section in document |
Who spoke
Colitis Australia · Gastroenterological Society · Australian Inflammatory Bowel Disease Association · Parallel- Group · Colitis Organisation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 32 of 43 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.